FDA Commissioner Margaret Hamburg talks about her experience as Commissioner of the FDA.
Friends of Cancer Research and the Engelberg Center for Health Care Reform at Brookings co-hosted discussions on critical issues in cancer care.
Researchers, drug developers, and patient advocates share their thoughts about Lung-MAP
Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way posible.
The FDA's Breakthrough Therapy program continues to accelerate the development and approval of groundbreaking new therapies.
Friends of Cancer Research's 2013 Annual Report is now available for download.
Patients, drug developers, and regulators discussed Breakthrough Therapy's progress at our May briefing
EBV-CTL - (Atara)
for the treatment of patients with rituximab-refractory, EBV-associated lymphoproliferative disease
Ibalizumab (TMB355) - (TaiMed)
for the treatment of HIV
Rindopepimut (Rintega) - (Celldex)
for the treatment of adult patients with EGFRvIII-positive glioblastoma (GBM)
FDA Commissioner Dr. Margaret Hamburg discussed her experience working with the FDA.
"There isn't a day where I'm not overwhelmed by how many people are dealing with this disease, and that's what drives all of our work at Friends of Cancer Research."
FRIENDS OF CANCER RESEARCH1800 M Street NW Suite 1050 | Washington, DC 20036202.944.6700